For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Tafamidis and the formulated version represents a significant breakthrough . These novel therapies protect the transthyretin protein, slowing its damaging build-up and alleviating t